Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Aripiprazole”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Study completedNCT00608543
What this trial is testing

Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression

Who this might be right for
Major Depressive Disorder
University of Texas Southwestern Medical Center 17
Large-scale testing (Phase 3)UnknownNCT01082848
What this trial is testing

ARIpiprazole in Anorexia NErvosa

Who this might be right for
Anorexia Nervosa
Juan A. Arnaiz 60
Large-scale testing (Phase 3)Study completedNCT00095719
What this trial is testing

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

Who this might be right for
DementiaAlzheimer's Disease
Otsuka Pharmaceutical Development & Commercialization, Inc. 125
Testing effectiveness (Phase 2)Ended earlyNCT00617058
What this trial is testing

Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

Who this might be right for
Weight Gain
University of North Carolina, Chapel Hill 1
Testing effectiveness (Phase 2)Study completedNCT00497055
What this trial is testing

Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals

Who this might be right for
Substance AbuseHIV Infections
San Francisco Department of Public Health 90
Large-scale testing (Phase 3)Ended earlyNCT02435836
What this trial is testing

A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

Who this might be right for
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. 631
Early research (Phase 1)Study completedNCT05804721
What this trial is testing

Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)

Who this might be right for
Healthy
Genuine Research Center, Egypt 29
Testing effectiveness (Phase 2)Study completedNCT00373880
What this trial is testing

Effects of Aripiprazole on Cocaine Craving and Self-Administration

Who this might be right for
Cocaine Abuse
New York State Psychiatric Institute 26
Post-approval studies (Phase 4)Ended earlyNCT03643159
What this trial is testing

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Who this might be right for
SchizophreniaBipolar 1 DisorderMajor Depressive Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. 2
Large-scale testing (Phase 3)Study completedNCT00332241
What this trial is testing

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

Who this might be right for
Autistic Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. 98
Large-scale testing (Phase 3)Study completedNCT01942148
What this trial is testing

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

Who this might be right for
Schizophrenia
Otsuka Pharmaceutical Co., Ltd. 68
Not applicableEnded earlyNCT02131415
What this trial is testing

Real Life Assessment of Abilify Maintena

Who this might be right for
Schizophrenia
Lundbeck Canada Inc. 200
Large-scale testing (Phase 3)Study completedNCT00292409
What this trial is testing

Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

Who this might be right for
Schizophrenia and Schizoaffective Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. 400
Not applicableStudy completedNCT05169268
What this trial is testing

Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

Who this might be right for
Schizophrenia and Related DisordersAnxiety Depression
The University of Hong Kong 6
Not applicableUnknownNCT03232710
What this trial is testing

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

Who this might be right for
Bioequivalence
Chengdu Kanghong Pharmaceutical Group Co., Ltd. 66
Post-approval studies (Phase 4)Study completedNCT00221962
What this trial is testing

Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

Who this might be right for
Attention Deficit Hyperactivity Disorder
University Hospitals Cleveland Medical Center 23
Post-approval studies (Phase 4)Study completedNCT00351936
What this trial is testing

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

Who this might be right for
Schizophrenia
North Suffolk Mental Health Association 16
Post-approval studies (Phase 4)Study completedNCT02360319
What this trial is testing

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

Who this might be right for
Schizophrenia
Vanguard Research Group 489
Post-approval studies (Phase 4)Study completedNCT03408873
What this trial is testing

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

Who this might be right for
Bipolar DisorderMedication AdherenceMedication Non Adherence
Martha Sajatovic 30
Large-scale testing (Phase 3)Study completedNCT00102518
What this trial is testing

Aripiprazole Open-Label, Safety and Tolerability Study

Who this might be right for
SchizophreniaBipolar Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. 325
Next Page